Cargando…
Clinical potential of necitumumab in non-small cell lung carcinoma
Despite significant progress, new therapeutic approaches for advanced non-small cell lung cancer (NSCLC) are highly needed, particularly for the treatment of patients with squamous cell carcinoma. The epidermal growth factor receptor (EGFR) is often overexpressed in NSCLC and represents a relevant t...
Autores principales: | Genova, Carlo, Hirsch, Fred R |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5012835/ https://www.ncbi.nlm.nih.gov/pubmed/27621656 http://dx.doi.org/10.2147/OTT.S114039 |
Ejemplares similares
-
Spotlight on necitumumab in the treatment of non-small-cell lung carcinoma
por: Thakur, Manish K, et al.
Publicado: (2017) -
Exposure–Response Analysis of Necitumumab Efficacy in Squamous Non‐Small Cell Lung Cancer Patients
por: Chigutsa, E, et al.
Publicado: (2017) -
Population Pharmacokinetics of Necitumumab in Cancer Patients
por: Long, Amanda, et al.
Publicado: (2016) -
Lung squamous cell carcinoma with severe hypomagnesemia due to cisplatin plus gemcitabine in combination with necitumumab therapy: A case report
por: Nakao, Akira, et al.
Publicado: (2021) -
The Budget Impact of Including Necitumumab on the Formulary for First-Line Treatment of Metastatic Squamous Non-Small Cell Lung Cancer: U.S. Commercial Payer and Medicare Perspectives
por: Bly, Christopher A., et al.
Publicado: (2018)